Table 2 Detail of vascular events in the 90 days of exposure for the triptans and control groups
From: Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events
| Ā | Triptan group (nā=ā24 774) | Control group (nā=ā99 096) | P value |
|---|---|---|---|
Number of vascular events, n (%) | 163 (0.66) | 523 (0.53) | Ā |
Acute cardiac events, n (%) | 75 (0.30) | 240 (0.24) | 0.43 |
Angina pectoris | 45 | 171 | Ā |
Acute myocardial infarction | 20 | 52 | Ā |
Other acute ischemic heart diseases | 10 | 17 | Ā |
Acute cerebral events, n (%) | 68 (0.27) | 146 (0.15) | 0.0009 |
Cerebral infarction | 51 | 101 | Ā |
Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction | 12 | 37 | Ā |
Stroke, not specified as haemorrhage or infarction | 5 | 8 | Ā |
Other vascular events, n (%) | 20 (0.08) | 137 (0.13) | 0.0002 |
Arterial embolism and thrombosis | 17 | 121 | Ā |
Other retinal vascular occlusions | 1 | 3 | Ā |
Acute vascular disorders of intestine | 1 | 9 | Ā |
Other peripheral vascular diseases | 1 | 4 | Ā |